“Cost-Per-Responder Analysis of Tralokinumab Versus Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis in the US and Canada”. SKIN The Journal of Cutaneous Medicine 8, no. 1 (January 16, 2024): s317. Accessed April 19, 2026. https://skin.dermsquared.com/skin/article/view/2397.